Male-biased aganglionic megacolon in the TashT mouse model of Hirschsprung disease involves upregulation of p53 protein activity and Ddx3y gene expression

Tatiana Cardinal, Karl-Frédéric Bergeron, Rodolphe Soret, Ouliana Souchkova, Christophe Faure, Amélinha Guillon, Nicolas Pilon

1 Molecular Genetics of Development Laboratory, Département des Sciences Biologiques, Université du Québec à Montréal (UQAM), Montréal, Québec, Canada, 2 Centre d’excellence en recherche sur les maladies orphelines–Fondation Courtois (CERMO-FC), Université du Québec à Montréal, Montréal, Québec, Canada, 3 Lipid Metabolism Laboratory, Département des Sciences Biologiques, Université du Québec à Montréal (UQAM), Montréal, Québec, Canada, 4 Département de pédiatrie, Université de Montréal, Montréal, Québec, Canada, 5 Division de gastroentérologie, hépatoLOGie et nutrition pédiatrique, Centre hospitalier universitaire Sainte-Justine, Montréal, Québec, Canada

*pilon.nicolas@uqam.ca

Abstract

Hirschsprung disease (HSCR) is a complex genetic disorder of neural crest development resulting in incomplete formation of the enteric nervous system (ENS). This life-threatening neurocristopathy affects 1/5000 live births, with a currently unexplained male-biased ratio. To address this lack of knowledge, we took advantage of the TashT mutant mouse line, which is the only HSCR model to display a robust male bias. Our prior work revealed that the TashT insertional mutation perturbs a Chr.10 silencer-enriched non-coding region, leading to transcriptional dysregulation of hundreds of genes in neural crest-derived ENS progenitors of both sexes. Here, through sex-stratified transcriptome analyses and targeted overexpression in ENS progenitors, we show that male-biased ENS malformation in TashT embryos is not due to upregulation of Sry—the murine ortholog of a candidate gene for the HSCR male bias in humans—but instead involves upregulation of another Y-linked gene, Ddx3y. This discovery might be clinically relevant since we further found that the DDX3Y protein is also expressed in the ENS of a subset of male HSCR patients. Mechanistically, other data including chromosome conformation captured-based assays and CRISPR/Cas9-mediated deletions suggest that Ddx3y upregulation in male TashT ENS progenitors is due to increased transactivation by p53, which appears especially active in these cells yet without triggering apoptosis. Accordingly, in utero treatment of TashT embryos with the p53 inhibitor pifithrin-α decreased Ddx3y expression and abolished the otherwise more severe ENS defect in TashT males. Our data thus highlight novel pathogenic roles for p53 and DDX3Y during ENS formation in mice, a finding that might help to explain the intriguing male bias of HSCR in humans.
Author summary

Hirschsprung disease (HSCR) is a life-threatening birth defect characterized by the lack of enteric neurons in the colon. HSCR is due to many gene defects, which are only partially understood. In particular, the reason why more boys than girls are affected by this condition is currently unknown. Yet, a better understanding of HSCR at the genetic/molecular level would help to develop more efficient therapies compared to current surgical approaches. Here, we identified a potential molecular cascade involving sequential upregulation of p53 and DDX3Y that, when inhibited, can eliminate the male bias in a HSCR mouse model. We found DDX3Y to be also specifically expressed in enteric neurons of a subset of male HSCR patients, suggesting that manipulation of the putative p53-DDX3Y pathway might eventually have therapeutic value in humans as well.

Introduction

Hirschsprung disease (HSCR), also known as aganglionic megacolon, is a severe male-biased congenital malformation where ganglia of the enteric nervous system (ENS) are missing from the rectum and over a variable length of the distal bowel [1, 2]. As the ENS normally controls patterns of smooth muscle contraction/relaxation along the entire gastrointestinal tract, the lack of ENS ganglia (aganglionosis) in the rectum and distal colon leads to functional obstruction and massive accumulation of fecal material in the proximal colon (megacolon). If left untreated, HSCR is lethal mostly because affected children eventually develop enterocolitis and sepsis [2]. Current treatment of HSCR is surgical removal of the distal aganglionic segment followed by anastomosis between a proximal region with ENS ganglia and the anal verge. Although this approach is usually life saving, there is a great need for alternative treatments since many of these children continue to have severe problems after surgery [3]. This calls for a better understanding of the pathogenic mechanisms underlying HSCR, which are not fully defined. The male bias of HSCR is especially poorly understood.

HSCR occurs because of incomplete colonization of the developing intestines by ENS progenitors—hereinafter named enteric neural crest cells (ENCCs) [4–6]. The vast majority of these progenitors are derived from neural crest cells of vagal origin [7, 8], with minor contingents also provided by neural crest cells of sacral origin [9] and by neural crest-derived Schwann cell precursors from extrinsic nerves [10]. In the mouse, ENCCs of vagal origin initially colonize the foregut around embryonic day (e) 9.5 and then migrate in the anteroposterior direction to reach the anal region by e14.5. From this stage onward, ENCCs of sacral and Schwann cell origin also enter the hindgut, but they cannot compensate for a lack of ENCCs of vagal origin [11]. For this reason, anything that perturbs colonization of the bowel by ENCCs of vagal origin results in aganglionosis over a varying length of the colon. Yet, for most HSCR patients, aganglionosis is restricted to the rectosigmoid colon [2]. This so-called short-segment form is also where the sex bias is more clearly observed, being about four times more common in boys than in girls [1].

The genetics of HSCR is complex, and far from being well understood. Numerous genes have been described to be involved, and most recent studies suggest that different combinations of rare and common variants in these genes are needed for the disease to occur [12–15]. Among this constantly expanding set of genes, those that code for members of GDNF/RET and EDN3/EDNRB signaling pathways have caught attention the most. However, mutations in these genes or in any other previously reported HSCR-associated genes cannot currently explain the strong male sex bias observed in the clinic. Accordingly, this male sex bias has been historically poorly replicated in animal models. A weak male bias has only occasionally been
detected in single and double mutant rodents bearing hypomorphic and/or dominant negative alleles of Ret and Ednrb [16–20]. In these models, the male bias affects extent of aganglionosis and rarely impacts megacolon expressivity, with the exception of a modest male to female ratio of about 1.5:1 in short-segment aganglionosis [17, 18]. A potential mechanism underlying these observations in rodents could be that the EDNRB pathway is by default slightly less active in the developing male bowel because of reduced expression of both Edn3 and Ec1 genes [20].

Other mechanisms that might explain the male bias of HSCR include downregulation of an X-linked gene or upregulation of a Y-linked gene [4]. For instance, a subset of patients suffering from CRASH syndrome-associated loss-of-function mutations of the X-linked gene L1CAM are known to also display HSCR [21–23]. However, the estimated incidence of HSCR among those patients is very low (~3%) and, in mouse models, L1cam has been shown to act as a modifier gene for aganglionosis-causing mutations of Sox10 but not for mutations of the major HSCR-associated genes Ret and Gdnf [24]. More recently, the Y-linked gene SRY also emerged as a possible candidate. Although this gene is best known as the key genetic switch for sex determination in the mammalian genital ridge [25], it is also believed to be involved in the etiology of diverse male-biased neurological disorders such as Parkinson’s disease and autism [26, 27]. In the context of HSCR, the regulatory sequences of human and pig SRY can drive reporter gene expression in the murine neural crest lineage [28, 29], and the SRY protein has been reported to be specifically expressed in the postnatal ENS from the proximal colon of a subset of male HSCR patients [30]. In vitro studies further revealed that human SRY can repress the RET promoter by preventing the formation of a SOX10-containing transcriptional complex [30]. However, transcriptome analyses of wild-type murine ENCCs show a complete absence of endogenous Sry expression [29, 31, 32]. Whether Sry/SRY expression may be upregulated in the developing ENS under certain circumstances, and whether such upregulation may play a causative pathological role in vivo both remain unanswered questions.

The TashT insertional mutant mouse line is a reliable model of short-segment HSCR that faithfully replicates key hallmarks of the human disease, such as partial penetrance of the megacolon phenotype [1, 29] and presence of an abnormal ENS (i.e., reduced neuronal density and increased proportion of nitrergic neurons) upstream of the aganglionic segment [33, 34]. Similar ENS defects are also observed in other models of short-segment HSCR like Ednrb-null and Holstein (a model for Trisomy 21 [Collagen VI]-associated HSCR) mouse lines [32, 35], and all three models show a similar dysbiotic gut microbiome profile mainly characterized by a robust increase of Proteobacteria at the expense of Firmicutes [36–38]. Yet, the TashT line is the only model that displays a robust male bias, not only for extent of colonic aganglionosis but also for megacolon expressivity [29, 34, 37]. Aganglionosis occurs in homozygous TashT Tg/Tg animals of both sexes due to slower migration of ENCCs [29]. This defect is slightly exaggerated in males, eventually culminating in a sex-associated difference of about 10–15% in length of ENS-covered colon that is clearly visible at birth [29]. In the end, megacolon is frequently observed in TashT Tg/Tg males and rarely observed in TashT Tg/Tg females, because more males than females fail to reach a threshold level of minimal intrinsic innervation of the colon, which is estimated to be around 80% of total colon length in the FVB/N genetic background [29, 37].

The TashT line has been obtained through an insertional mutagenesis screen for new genes important for neural crest development [39]. The TashT transgene insertion site is located in the vicinity of a block of three conserved silencer elements within the Hace1-Grik2 intergenic region on chromosome 10, resulting in massive dysregulation of the ENCC transcriptome [29]. More specifically, the mutagenic TashT insertion was found to disrupt a far-cis chromatin interaction normally occurring between this silencer-enriched region and Fam162b located at 3.6Mb away, presumably explaining why this poorly characterized gene is upregulated in TashT Tg/Tg ENCCs [29]. However, neural crest-specific overexpression of Fam162b via
transient transgenesis only had a modest negative impact on extent of ENCC colonization in the distal colon [29], suggesting that other gene(s) might also be primary target(s) of the TashT insertional mutation, and might thus also contribute to the TashT Tg/Tg phenotype.

Here, we further analyzed TashT Tg/Tg ENCCs as a function of animal sex, with the main goal of identifying the molecular cause of the TashT male bias. Mainly based on unbiased high-throughput approaches and new genetically-modified mouse models, this work led to the identification of the Y-linked gene Ddx3y as the likely causal gene of the TashT male bias. This work further suggests that sequential upregulation of p53 protein activity and Ddx3y gene expression is a reversible pathogenic mechanism in the TashT ENS, and correlative expression data show that such mechanism might also potentially be at work in human HSCR.

Results

Ddx3y is a prime candidate for explaining the male bias of aganglionic megacolon occurrence in TashT mice

To identify the molecular cause for the male bias in TashT Tg/Tg animals, we first analyzed global gene expression in TashT Tg/Tg ENCCs as a function of sex. As per our prior work [29], TashT Tg/Tg ENCCs were recovered from e12.5 stomachs and small intestines by FACS (fluorescence-activated cell sorting) owing to the presence of a SRY promoter-driven fluorescent reporter (pSRYp[1.6kb]-YFP) that specifically labels neural crest derivatives [28]. Prior to cell sorting, embryos were sexed by visual inspection of the dimorphic developing gonads, which are easy to distinguish at e12.5 thanks to the presence of testis-specific features such as the coelomic vessel and testis cords. Pools of sexed ENCC samples were then processed for rRNA-depleted RNA-seq, and sequencing results were analyzed to detect differentially-expressed genes. Very interestingly, comparison of this novel [Male]TashT Tg/Tg vs [Female]TashT Tg/Tg dataset (8 genes differently expressed >1.5-fold at P≤0.05) with our previously described [29] unsexed TashT Tg/Tg vs-Control dataset (2075 genes differently expressed >1.5-fold at P≤0.05) identified the Y-linked Ddx3y as the only gene significantly dysregulated in both analyses (Fig 1A and 1B and S1 and S2 Datasets). This DEAD-box RNA helicase coding gene is upregulated in male TashT Tg/Tg ENCCs, and together with three neighbour genes from the short arm of the Y chromosome (Kdm5d, Eif2s3y, and Uty) define the Y-linked gene expression signature of ENCCs [29]. Once again, Sry expression was not detected in this transcriptome analysis (S1 Dataset). We also noted apparently robust basal expression of Ddx3y, Eif2s3y, Uty and Kdm5d in the female TashT Tg/Tg dataset (Fig 1B), most likely due to erroneous mapping of sequencing reads from their highly similar X-linked homologs (Ddx3x, Kdm5c, Eif2s3x and Utx). RT-qPCR validation of RNA-seq data in male e12.5 ENCCs recovered by FACS was thus performed using primer pairs specific to Y-linked homologs, which confirmed that Ddx3y, but not its neighbours Uty and Eif2s3y, is specifically upregulated in male TashT Tg/Tg ENCCs in comparison to Gata4p-GFP control ENCCs [29, 40] of the same sex (Fig 1C and 1D).

Although a fully sex-stratified RNA-seq approach (i.e., comparing TashT Tg/Tg males and females to control males and females, respectively) might potentially have identified additional genes, all of the above gene expression data strongly suggest that specific upregulation of Ddx3y in male TashT Tg/Tg ENCCs might contribute to the male bias in extent of aganglionosis, and megacolon expressivity subsequently observed in postnatal animals.

Overexpression of Ddx3y, but not Sry, plays a pathogenic role in male TashT Tg/Tg ENCCs

To assess a potential pathogenic role for Ddx3y overexpression in ENCCs, we generated transgenic mice in which a Myc-tagged version of DDXY was expressed as part of a bicistronic
construct also allowing expression of eGFP (enhanced green fluorescent protein). To direct expression of this \textit{MycDdx3y-IRES-eGFP} cassette in ENCCs, we constructed a novel synthetic promoter consisting of fused Sox10 [41] and Ednrb [42] neural crest enhancers upstream of the Hsp68 minimal promoter [43]. Having previously used a similar Sox10-U3 enhancer-based system but with mitigated success [29, 31], we reasoned that adding the ENCC-specific Ednrb enhancer would increase expression levels and specificity (S1A and S1B Fig). Activity of this novel synthetic promoter and expression of the \textit{MycDdx3y-IRES-eGFP} cassette were tested in neural crest-derived Neuro2a cells, which confirmed proper cytoplasmic enrichment of Myc-DDX3Y protein [44] and co-expression with eGFP (S1C Fig). Through standard transgenesis, three founder animals were then obtained and used to generate independent lines. For each line, intestines from e10.5–12.5 transgenic embryos were first screened for eGFP fluorescence, which was undetectable in all cases. Expression of the \textit{MycDdx3y-IRES-eGFP} transgene in e12.5 ENCCs was nonetheless confirmed for all three lines via RT-qPCR, which further revealed variable levels of expression in each line (S1D Fig). Moreover, we confirmed expression of \textit{MycDdx3y} protein via anti-Myc tag immunofluorescence staining of freshly dissociated e12.5 intestines (see results for line #3 in S2 Fig). For each line, both heterozygous \((\text{MycDdx3y}^{\text{Tg}+/\text{Tg}})\) and homozygous \((\text{MycDdx3y}^{\text{Tg}/\text{Tg}})\) transgenic animals were viable and fertile, without any sign of megacolon in rodents (e.g., hunched posture, lethargy, distended abdomen). Accordingly, staining of acetylcholinesterase (AChE) activity in the myenteric plexus revealed an overall normal ENS structure in each line, regardless of animal sex (S3 Fig). However, in a \textit{TashT^{\text{Tg}/\text{Tg}}} sensitized background, heterozygous presence of the \textit{MycDdx3y-IRES-eGFP} transgene from any of the transgenic lines increased megacolon incidence in P18-P50 males (Fig 1E and S1E Fig). The proportion of affected animals reached 37.5% (3/8) for line #1, 75% (6/8) for line #2, and 60% (3/5) for line #3, collectively resulting in a 2.5-fold increase in megacolon incidence from 23% (3/13) of \textit{TashT^{\text{Tg}/\text{Tg}}} males to 57% (12/21) of all male \textit{TashT^{\text{Tg}/\text{Tg}}, MycDdx3y^{\text{Tg}+/\text{Tg}}} mice. This collective increase in megacolon incidence was associated with more extensive aganglionosis as assessed via staining of AChE activity in the myenteric plexus (Fig 1E). Each individual line showed an increase in the average extent of aganglionosis, although statistical significance was not reached for lines #1 and #3 most likely because of small sample size (S1E Fig). Nonetheless, extent of aganglionosis was in each case sufficient to markedly increase the proportion of animals not reaching the minimal length of intrinsic innervation necessary to avoid blockage (~80% in the FVB/N genetic background [29]; see dashed lines in Fig 1E and S1E Fig). Intriguingly, neither megacolon incidence nor extent of aganglionosis were affected by the presence of \textit{MycDdx3Y} in female \textit{TashT^{\text{Tg}/\text{Tg}}} animals (Fig 1F and S5 Fig).

Based on the results above, we reasoned that this approach would be ideal to also test the candidacy of \textit{Sry} as another Y-linked gene potentially involved in the male bias of HSCR [30]. To address the lack of \textit{in vivo} evidence about a causative pathogenic role for \textit{Sry} in the...
developing ENS, we substituted $\text{Myc}_\text{Ddx3y}$ for $\text{Myc}_\text{Sry}$ in the bicistronic construct described above (S6A Fig) and tested the impact of its overexpression in the $\text{TashT}^{\text{Tg/Tg}}$ sensitized background. As above, the $\text{Myc}_\text{Sry-IRES-eGFP}$ construct was first tested in Neuro2a cells, which confirmed proper nuclear localization of $\text{Myc}_\text{SRY}$ protein [45] and co-expression with eGFP (S6B Fig). Standard transgenesis then yielded a single founder animal that was used to derive a stable line, in which we confirmed expression of the $\text{Myc}_\text{Sry-IRES-eGFP}$ cassette in the developing peripheral nervous system (including the ENS) by virtue of the presence of eGFP fluorescence in e11.5 embryos (S6C Fig). Again, neither $\text{Myc}_\text{Sry}^{\text{Tg/Tg}}$ nor $\text{Myc}_\text{Sry}^{\text{Tg/+}}$ animals showed a megacolon phenotype. Furthermore, in contrast to our findings with the $\text{Myc}_\text{Ddx3y-IRES-eGFP}$ transgene, expression of the $\text{Myc}_\text{Sry-IRES-eGFP}$ construct in the $\text{TashT}^{\text{Tg/Tg}}$ background had no impact on megacolon incidence, extent of aganglionosis or ENS patterning in P18-P50 mice, regardless of animal sex (Fig 1G and 1H and S3–S5 Figs). This work thus suggests that $\text{Myc}_\text{SRY}$ is unable to significantly affect murine ENS development in vivo, even when expressed in a sensitized genetic background and at higher levels than $\text{Myc}_\text{DDX3Y}$ (based on detection of eGFP fluorescence, which further revealed extensive overlap with SOX10$^+$ cells; S7 Fig).

Another conclusion of these studies is that only a modest increase of DDX3Y amounts appears sufficient to impair male ENS development in a sensitized genetic background.

**DDX3Y is expressed in human enteric neurons from a subset of male HSCR patients**

To verify whether our findings in mice might be clinically relevant, we then evaluated whether the DDX3Y protein is expressed in colon tissues resected from human HSCR patients with short-segment aganglionosis. Although DDX3Y would be expected to have a pathogenic role before birth (i.e., during ENS formation), we reasoned that at least some residual expression might still be detectable in male HSCR tissues a few weeks/months after birth. DDX3Y expression was assessed by immunofluorescence in two distinct cohorts of HSCR patients, including one previously described [32]. A total of 16 tissues were analyzed (14 from boys and 2 from girls), focusing on the ENS-containing region in the intermediate zone just upstream of the aganglionic region, and using the pan-neuronal marker PGP9.5 to identify enteric neurons. As expected, DDX3Y was not detected in enteric neurons from female samples, which were used as negative controls (Fig 2 and Table 1). In marked contrast, variable levels of DDX3Y protein were detected in enteric neurons from half of male patients (Fig 2 and Table 1). Although a definitive answer about the exact proportion of male patients overexpressing DDX3Y would require an analysis of prenatal HSCR tissues (which is impracticable given that HSCR is diagnosed only after birth), these observations in postnatal tissues support the possibility that DDX3Y might play a pathogenic role in the male bias of human HSCR, as it does in the TashT mouse line.

**Ddx3y expression is not directly regulated by the Hace1-Grik2 silencer-enriched region in mice**

Having discovered that $\text{Ddx3y}$ upregulation is likely playing a role in the TashT megacolon male bias and that the corresponding protein might also potentially contribute to human HSCR, we next sought to determine the cause of this upregulation assuming that the TashT insertion site was somehow involved. This transgenic insertion is located within the Hace1-Grik2 intergenic region on chromosome 10, interfering with three conserved silencer elements [29]. As this silencer-enriched region can normally interact with remote genomic regions of chromosome 10 [29], we first hypothesized that they could also directly interact with the $\text{Ddx3y}$ locus and thereby actively attenuate its expression during normal ENS formation in
Fig 2. The DDX3Y protein is present in enteric neurons from the intermediate zone in a subset of HSCR patients. Representative confocal images of DDX3Y and PGP9.5 double immunofluorescence labeling of enteric neurons in sigmoid colon tissues resected from female (ID #H2) and male (ID #SJH2) HSCR patients. All displayed images represent a single focal plane and dashed outline marks area occupied by a single ganglion. Scale bar, 50 μm.

https://doi.org/10.1371/journal.pgen.1009008.g002

Table 1. Overview of HSCR colon samples used for assessing DDX3Y expression.

| Cohort               | ID  | Age at surgery (days) | Sex | DDX3Y expression |
|----------------------|-----|-----------------------|-----|------------------|
| Soret et al. [32]    | H11 | 35                    | F   | -                |
|                      | H2  | 75                    | F   | -                |
|                      | H1  | 17                    | M   | -                |
|                      | H8  | 20                    | M   | +                |
|                      | H5  | 40                    | M   | -                |
|                      | H12 | 42                    | M   | -                |
|                      | H4  | 51                    | M   | +                |
|                      | H10 | 63                    | M   | -                |
|                      | H7  | 96                    | M   | +                |
|                      | H9  | 222                   | M   | +                |
|                      | H3  | 321                   | M   | -                |
|                      | H6  | 454                   | M   | -                |
| Ste-Justine Hospital | STH1| 22                    | M   | +                |
|                      | STH2| 36                    | M   | +                |
|                      | STH3| 80                    | M   | -                |
|                      | STH4| 349                   | M   | +                |

https://doi.org/10.1371/journal.pgen.1009008.t001
male embryos. A corollary of this hypothesis would be that the TashT transgenic insertion prevents this inter-chromosomic interaction, leading to relief of Ddx3y repression in male TashT$^{Tg/Tg}$ ENCCs. To verify this possibility and potentially identify other relevant interactions with the Hace1-Grik2 silencer-enriched region, we turned to a circular chromatin conformation capture–high-throughput sequencing (4C-seq) approach [46]. PCR-based pilot assays were first performed in Neuro2a cells in order to test several potential bait sequences located within or around the silencer-enriched region (S8 Fig), from which we chose a 481bp region located between two silencer elements that fulfilled all selection criteria for 4C-seq [46]. To allow comparison with our prior RNA-seq data, the 4C-seq analysis was then performed on FACS-recovered e12.5 ENCCs pooled from either Gata4p-GFP control or TashT$^{Tg/Tg}$ mutant embryos, again as a function of sex. Given that none of the dysregulated genes from TashT$^{Tg/Tg}$ ENCCs is in the immediate vicinity of the Hace1-Grik2 intergenic region [29], analysis of captured sequences was focused on far-cis (>10kb) and trans interactions using a modified version of the W4Cseq pipeline [47]. This analysis did identify chromatin contacts between the Hace1-Grik2 silencer-enriched region and the Ddx3y locus (Fig 3A and S3 Dataset). However, such interactions appeared to be present in both Gata4p-GFP control and TashT$^{Tg/Tg}$ ENCCs, irrespective of sex—most likely because of erroneous mapping of homologous sequences from the X chromosome as observed in sex-stratified RNA-seq data (Fig 1B). This result thus invalidated our primary hypothesis that Ddx3y upregulation in male TashT$^{Tg/Tg}$ ENCCs could be caused by transgene insertion-mediated disruption of a direct functional interaction with the silencer-enriched region. Yet, many gains and losses of chromatin interactions were identified when comparing Gata4p-GFP control and TashT$^{Tg/Tg}$ ENCCs as a function of sex (S4 Dataset), suggesting the possibility of an indirect regulatory mechanism.

**Deletion of the Hace1-Grik2 silencer-enriched region does not cause colonic aganglionosis in mice**

Since our 4C-seq analysis identified many gains and losses of chromatin contacts with the Hace1-Grik2 silencer-enriched region, we surmised that the TashT transgene insertion event causing the megacolon phenotype interferes with normal chromatin interactions and/or triggers new ectopic interactions. To directly test if interaction losses contribute to the megacolon phenotype, we generated mice lacking a 23kb genomic fragment that spans the whole silencer-enriched region from the Hace1-Grik2 intergenic region (Fig 3B). Through CRISPR/Cas9 targeting, seven founder animals were obtained from which three were used to generate independent lines. In each case, mice homozygous for the deletion (Hace1-Grik2$^{ΔSER/ΔSER}$) were viable and fertile. Hace1-Grik2$^{ΔSER/ΔSER}$ mice also displayed a normally formed ENS in both male and female animals, as assessed in adults via staining of AChE activity in the myenteric plexus (Fig 3C and S9A Fig) and in e12.5 embryos via βIII-Tubulin immunofluorescence staining of ENCCs (Fig 3D and S9B Fig). This negative result thus suggests that neither the TashT megacolon phenotype nor its male bias are caused by a transgenic insertion-induced loss of chromatin interaction. This further suggests that the TashT male-biased megacolon phenotype is instead due to a transgenic insertion-induced gain of chromatin interaction.

**Ddx3y upregulation in male TashT$^{Tg/Tg}$ ENCCs may be explained by a gain of interaction between the Hace1-Grik2 silencer-enriched region and the p53 phosphatase coding gene Dusp26**

To explore the contribution of ectopic transgenic insertion-induced chromatin interactions to the male-biased TashT megacolon phenotype, we cross-compared our four 4C-seq datasets and focused our attention on 455 genes with which chromatin interaction gains were observed
Fig 3. Ddx3y expression is not directly regulated by the Hace1-Grik2 silencer-enriched region on mouse chromosome 10. (A) Overview of sex-stratified 4C-seq analysis of far-cis (red) and trans (blue) interactions with the Chr.10 Hace1-Grik2 silencer-enriched region in e12.5 ENCCs, which were recovered by FACS from 44x109 to 576x714.
in male *TashT*ΔSER ENCCs (Fig 4A). Further cross-comparison of this gene set (see tabs "Unique to M-TashT (317)" and "Common to M- & F-TashT (138)" in S4 Dataset) with our prior unsexed *TashT*ΔSER vs-Control RNA-seq dataset (S2 Dataset) identified 14 genes for which expression was downregulated in *TashT*ΔSER ENCCs (Fig 4B and Table 2), as it would be expected from direct functional interaction with the *Hace1-Grik2* silencer-enriched region. From these 14 genes, *Dusp26* on chromosome 8 stood out as the best candidate (Fig 4C) based on its known phosphatase activity that inhibits p53 [48–50] and the fact that p53 can activate the expression of *DDX3X* [51, 52], the X-linked homolog of *DDX3Y*. A direct interaction between the *Dusp26* locus and the *Hace1-Grik2* silencer-enriched region was independently validated to be *TashT*-specific using chromosome conformation capture (3C)-PCR assays, which further revealed that it can occur in both male and female *TashT*ΔSER samples at e12.5 (Fig 4D).

The discovery of a putative repressive interaction between the *Hace1-Grik2* silencer-enriched region and the p53 phosphatase coding gene *Dusp26* in *TashT*ΔSER ENCCs prompted us to analyse p53 protein levels in these cells. As expected from the downregulation of a p53 inhibitor, immunofluorescence analyses revealed that the number of e12.5 ENCCs with high levels of p53 protein (a proxy for stabilized/activated p53 protein [53, 54]) is on average doubled in *TashT*ΔSER embryos in comparison to *Gata4p-GFP* controls (Fig 4E). This increase seems specific to the p53 protein as *Trp53* transcript levels remain grossly unaffected by the *TashT* mutation in unsexed e12.5 ENCCs (3222 read counts in *TashT*ΔSER vs 3544 read counts in *Gata4p-GFP* controls; *P = 0.69*) [29]. The increase in p53 protein levels was present in both sexes, affecting about 9% of ENCCs in *TashT*ΔSER embryos compared to about 3–5% in *Gata4p-GFP* controls (Fig 4F). Yet, a sex-specific difference was specifically noted in *Gata4p-GFP* controls, with male embryos having half the number of ENCCs with high levels of p53 protein in comparison to female embryos (Fig 4F).

We next sought to determine whether murine *Ddx3x* and *Ddx3y*, like human *DDX3X* [51], could be directly regulated by p53. An important sub-question we also wanted to address was whether *Ddx3y* could be more sensitive than *Ddx3x* to p53 regulation, as this would help to explain why *Ddx3x* expression in ENCCs is not affected by the *TashT* mutation [29]. To begin answering these questions, we analyzed the impact of p53 knockdown on the expression of both *Ddx3x* and *Ddx3y* in three male embryonic cell lines (R1 embryonic stem cells, F9 embryonic carcinoma cells, and P19 embryocarcinoma cells) via RT-qPCR. Neural crest-derived Neuro2a cells were not included in these analyses because of their lack of a Y chromosome (S10 Fig). Interestingly, expression of *Ddx3x* appeared more affected than *Ddx3y* by siRNA-mediated knockdown of p53 in both R1 and F9 cells (Fig 4G). Accordingly, chromatin immunoprecipitation (ChIP)-qPCR analyses in R1 cells further revealed a trend toward a greater transfection stress-induced interaction of p53 with the *Ddx3y* promoter in comparison to the *Ddx3x* promoter, or even the *Mdm2* promoter—a well known stress-induced p53 target [55] (Fig 4H). Collectively, these results thus support a model whereby increased p53 activation in *TashT*ΔSER ENCCs leads to male-specific upregulation of the Y-linked gene *Ddx3y*, and not its X-linked homolog *Ddx3x*, because the *Ddx3y* promoter is more prompt to respond to p53.
Inhibition of p53 activity eliminates the male bias in TashT\textsuperscript{Tg/Tg} embryos

To directly test the predicted p53 contribution to the male-biased severity of the TashT ENCC colonization defect, we turned to a pharmacological approach that previously proved to be efficient in a mouse model of Treacher-Collins syndrome—a known p53-dependent neurocrystopathy [56]. To this end, pregnant TashT\textsuperscript{Tg/Tg} dams were administered the synthetic p53 inhibitor pifithrin-α (2 mg/kg of body weight) or vehicle only (DMSO) via daily intraperito-
neal injections for 7 consecutive days, from e8.5 to e14.5. The idea was to expose vagal-derived ENCCs during their entire migration phase, from the neural tube to the distal hindgut.

Embryos were then collected at e15.5 and their colon was immediately analyzed for extent of ENCC colonization without fixation, taking advantage of the endogenous YFP labeling of these cells in TashT embryos [29]. In accordance with our prior observations in TashT\textsuperscript{Tg/Tg} newborns [29], a statistically significant difference of about 14.5% in extent of ENCC colonization was noted between male (59.5% ± 1.8%) and female (74.0% ± 2.8) TashT\textsuperscript{Tg/Tg} embryos of the vehicle-treated group (Fig 5A and 5B). Remarkably, this difference was completely

Table 2. List of the 14 downregulated genes in TashT\textsuperscript{Tg/Tg} ENCCs also found in the male TashT\textsuperscript{Tg/Tg} 4C-seq analysis.

| Gene   | Fold change | TashT mean count | Control mean count |
|--------|-------------|------------------|-------------------|
| Lrnn2  | -2.84       | 113              | 321               |
| Dusp26 | -2.74       | 533              | 1462              |
| Nfasc  | -2.72       | 1696             | 4613              |
| Prox1  | -2.56       | 142              | 365               |
| Pnmal1 | -2.56       | 228              | 583               |
| Hoxd3  | -2.24       | 2885             | 6454              |
| Ctn2   | -2.22       | 161              | 357               |
| Rbp1   | -2.21       | 6474             | 14329             |
| Slc35e4| -2.16       | 250              | 539               |
| Tspan7 | -2.13       | 1359             | 2893              |
| Bbc3   | -1.98       | 135              | 267               |
| Mvb12b | -1.74       | 2755             | 4811              |
| Pik3ip1| -1.66       | 687              | 1142              |
| Prps2  | -1.59       | 3779             | 6011              |

https://doi.org/10.1371/journal.pgen.1009008.t002
eliminated by pifithrin-α treatment. In this group, the average extent of ENCC colonization in both male (73.1% ± 2.9%) and female (73.5% ± 4.4%) TashTg/Tg embryos appeared very similar to what was observed in vehicle-treated female TashTg/Tg embryos (Fig 5A and 5B).

To verify the potential involvement of Ddx3y in the response to pifithrin-α treatment, we evaluated its expression in male ENCCs recovered by FACS (owing to YFP fluorescence) from stomach and small intestine during the treatment period at e12.5. As observed upon siRNA-mediated knockdown of p53 expression in R1 and F9 cell lines (Fig 4G), RT-qPCR analysis

---

**Fig 5. In utero pifithrin-α treatment improves colon colonization by TashTg/Tg ENCCs in a male-specific manner.** (A) Representative confocal images of YFP-labeled ENCCs in the colon of male and female e15.5 TashTg/Tg embryos that were exposed to either pifithrin-α or only vehicle (DMSO). The white arrow indicates the migration front of vagal-derived ENCCs. Scale bar, 500 μm. (B) Sex-stratified quantitative analysis of vagal-derived ENCC colonization (in % of total colon length) using images such as those displayed in A. (C-D) RT-qPCR analysis of endogenous mRNA expression of Ddx3y (C) and Ddx3x (D) genes in TashTg/Tg ENCCs recovered by FACS from male embryos exposed to pifithrin-α or only vehicle (DMSO), either during (e12.5) or after (e15.5) the treatment period. (E) Correlation between Ddx3y expression levels in ENCCs and extent of ENCC colonization in the colon for e15.5 male TashTg/Tg embryos that were exposed to pifithrin-α. (R, Pearson’s correlation coefficient; *P<0.05; ***P<0.001; n.s., not significant; Student’s t-test).

https://doi.org/10.1371/journal.pgen.1009008.g005
revealed a significant decrease in Ddx3y gene expression upon pharmacological inhibition of p53 activity (Fig 5C). When we performed the same analysis using a subset of e15.5 embryos that were previously evaluated for ENCC colonization (Fig 5A and 5B), we also detected a trend toward decreased expression of Ddx3y (Fig 5C) which was further found to be inversely correlated with extent of colonization (Fig 5E). In marked contrast, analysis of Ddx3x gene expression in response to pifithrin-α treatment gave inconsistent results in this experimental setting, showing a downregulation during the treatment period at e12.5 and an upregulation after treatment termination at e15.5 (Fig 5D). All these in vivo data thus strengthen the idea that DDX3Y, but not DDX3X, is likely involved in a p53-regulated molecular cascade that is responsible for the increased severity of the TashT ENCC colonization defect in male embryos.

Discussion

The TashT mouse line is unique in being the only mouse model of HSCR that replicates the male bias observed in humans [29, 34, 37]. Here, we report that the male bias in TashT mice involves the upregulation of the Y-linked gene Ddx3y in ENCCs, and that the human DDX3Y protein is also expressed in the postnatal ENS of a substantial subset of HSCR patients. In the course of our studies, we also found that overexpression of the murine ortholog of SRY—another Y-linked candidate gene for the HSCR male bias—has no overt impact on ENS formation in mice. Our mechanistic studies further suggest that Ddx3y is a preferred target gene of p53, and that pharmacological inhibition of this transcription factor in utero is sufficient to eliminate the TashT male bias. This work thus identifies p53 and DDX3Y as new players in aganglionic megacolon pathogenesis in mice, a finding that might eventually be useful for the development of non-surgical therapies in humans.

Upregulation of the Y-linked SRY gene has been previously proposed as a pathogenic mechanism for the HSCR male bias [30]. However, this hypothesis was solely based on in vitro studies and protein expression data in HSCR colon tissues, without any functional assay in vivo. Moreover, no ENS defects were reported in mice with ubiquitous overexpression of human SRY, which die around two weeks of age due to multi-organ failure mainly affecting the heart, liver, lung and brain [57]. To validate the candidacy of SRY in the HSCR male bias, we thus decided to directly test whether mouse Sry can negatively impact ENS development in mice via targeted overexpression in the neural crest lineage (S6 Fig). Importantly, this work revealed no influence of Sry on ENS formation, even in a TashT sensitized background (Fig 1G and 1H and S3–S5 Figs). Combined to the fact that Sry is not normally expressed in murine ENCCs when aganglionic megacolon develops (S1 Dataset), our negative finding thus suggests that the SRY protein is not involved in the HSCR male bias. Yet, it remains also possible that SRY only affects human and not murine ENS development. Moreover, these observations do not rule out a potential pathogenic role for SRY in the mature ENS, and the idea that Parkinson’s disease may originate from ENS dysfunctions that propagate to the brain is especially interesting in this regard [58]. Indeed, human SRY is expressed in both the postnatal ENS [30] and midbrain-associated dopaminergic neurons [59], and antisense oligonucleotide-mediated knockdown of Sry is neuroprotective in experimental Parkinson’s disease in rats [27].

In contrast to our negative results with mouse Sry, several lines of evidence suggest that upregulation of the DEAD-box RNA helicase coding gene DDX3Y might be involved in the HSCR male bias: 1) murine Ddx3y is normally expressed in ENCCs when aganglionic megacolon develops (S2 Dataset); 2) Ddx3y is specifically upregulated in TashT ENCCs (Fig 1A–1C and S1 Dataset); 3) neural crest-directed overexpression of Ddx3y worsens the TashT male
bias in extent of aganglionosis and incidence of megacolon (Fig 1E and S1E Fig); 4) pifithrin-α-induced elimination of the TashT male bias in extent of aganglionosis is associated with decreased Ddx3y expression (Fig 5); and 5) the human DDX3Y protein is detected in enteric neurons of an important subset of HSCR patients (Fig 2 and Table 1). Of note, this latter observation challenges the view that the DDX3Y gene is widely transcribed, but that the protein is restricted to male germ cells [60]. However, it is important to point out that this conclusion was based on western blot analysis of only three male adult tissues (brain, kidney and testis). Since then, other groups have reported the presence of the DDX3Y protein in supplemental cell lineages, such as different types of myeloid and lymphoid hematopoietic cells [61, 62] and neurons derived from NTera2 embryocarcinoma cells [44].

The exact molecular mechanism by which DDX3Y may contribute to the development of aganglionic megacolon in a sensitized genetic background is currently unknown. The RNA helicase function of both DDX3Y and DDX3X (also known as DDX3) is believed to influence many aspects of RNA processing from transcription to translation, with an especially prominent role in the regulation of initiation of translation [63, 64]. Yet, although these proteins are highly similar (>90% sequence similarity), they are only partially redundant [65–67], meaning that DDX3Y is expected to have its own set of target transcripts. However, very little is known about the specific molecular role of DDX3Y. This situation thus makes the analysis of DDX3Y function in NTera2-differentiated neurons especially interesting for predicting DDX3Y’s potential function in ENCCs. Indeed, as we observed in neural crest-derived Neuro2a cells (S1C Fig), the DDX3Y protein is enriched in the cytoplasm in NTera2-differentiated neurons, and knocking down DDX3Y in these cells impacts the translation of 71 proteins [44]. Interestingly, many of these proteins play various regulatory roles in cell migration (e.g., RAB5B, RAB5C, CNN2, IFITM1, COX2, PKM1, BCA1, SMAP1, ENO1, RAP2A, ANP32A, and STMN1), which is the main cellular process affected in TashT Tg/Tg ENCCs [29]. The fact that no transcripts other than Ddx3y are specifically dysregulated at the transcriptional level in male TashT Tg/Tg ENCCs (Fig 1A) supports the idea that DDX3Y mainly influences translation of migration regulatory proteins in these cells as well. As observed in NTera2-differentiated neurons [44], it can further be hypothesized that an excess of DDX3Y might result in either an increase or a decrease in translation efficiency depending of the mRNA target. Identification of these post-transcriptionally regulated mRNA targets of DDX3Y in ENCCs will require further high-throughput experiments that are beyond the scope of the current study, such as proteomics-based studies combined to RNA-binding and ribosome profiling assays. This future work should also lead to a better understanding of the very intriguing observation that DDX3Y overexpression has no impact in a female TashT Tg/Tg background. Different possibilities include the existence of either male-specific Y-linked mRNA target(s) or X-linked mRNA target(s) that escape X inactivation [68], which in both cases would make the encoded protein(s) more vulnerable to pathogenic perturbations in males. Another possibility would be that DDX3Y must act in concert with another male-specific Y-linked protein involved in initiation of translation, such as the EIF2 subunit EIF2S3Y [69, 70].

We put a lot of efforts on elucidating the molecular mechanism by which Ddx3y may be upregulated in male TashT Tg/Tg ENCCs, reasoning that this might eventually be useful for therapeutic purposes. This work culminated on the identification of an apparently critical role for p53, which was previously reported as a key regulator of DDX3X transcription in lung cancer cells [51, 52]. Our data now show that Ddx3y transcription can similarly be regulated by p53 in male embryonic cell lines of mouse origin, and the magnitude of this regulation even appears to be more important than for Ddx3x (Fig 4G and 4H). This observation is in accordance with a previous study reporting differential regulation of the DDX3Y and DDX3X promoters in various human and hamster cell lines [65], and further suggests that the importance of p53
regulation for Ddx3x/DDX3X expression might be context-dependent (e.g., cell type- or stage-specific). In male ENCCs, p53 appears especially important for the regulation of Ddx3y expression, but not for the regulation of Ddx3x expression. Ddx3y expression levels always seem in phase with p53 activation levels in TashT^GFP ENCCs: both are upregulated when compared to basal levels in Gata4p-GFP control ENCCs (e.g., Fig 1C for Ddx3y gene expression and Fig 4E and 4F for p53 protein activity) and both are downregulated upon pifithrin-α treatment (Fig 5C). In contrast, Ddx3x expression levels appear either unaffected by the presence of the TashT mutation [29] or inconsistently modulated by pifithrin-α-mediated inhibition of p53 activity (Fig 5D). The close regulatory interaction between p53 and Ddx3y, combined to the detrimental impact that DDX3Y may have on colonization of male ENCCs (Fig 1E), might be one reason why p53 activity in control ENCCs appears to be lower in male than in female samples (Fig 4F). Such a safeguard mechanism would help reducing the risk that Ddx3y expression reaches pathogenic levels in male ENCCs.

Although we became interested in p53 because of the TashT mutation-mediated transcriptional downregulation of its inhibiting phosphatase DUSP26 (Fig 4B–4D and Table 2), our work does not rule out the possibility that other cellular stresses might also have contributed to the increased activation of p53 in ENCCs. Indeed, p53 can be activated by a plethora of cellular stresses [71], and increasing evidence points to inappropriate activation of p53 as the underlying cause of many developmental syndromes collectively referred to as p53-associated syndromes [72]. Most of these syndromes involve defective neural crest development [72], which appears to be due to the fact that this cell lineage is especially susceptible to p53 activation [73]. Accordingly, experimentally-induced moderate activation of p53 in either pre-migratory or migratory neural crest cells dramatically decreases their number, including those contributing to ENS formation [72]. This phenomenon appears mostly due to an increase in p53-induced apoptosis [72, 73]. However, ENCCs are known to become resistant to p53-induced apoptosis after their entry into the foregut [74], an observation that helps to explain why TashT^GFP ENCCs do not have any survival deficit [29] despite showing an increase in p53 activation (Fig 4E and 4F). Altogether these observations thus support a general model whereby many different HSCR-causing mutations might trigger p53 activation in ENCCs and lead to a preferential increase of DDX3Y expression in males (along with its detrimental effects on ENCC colonization), without affecting canonical apoptosis-associated p53 target genes. Although it remains challenging to test this gene defect-independent hypothesis with the relevant human cell type, this can now be envisaged thanks to recent methods for in vitro differentiation of ENS progenitors from pluripotent stem cells (using either ES or iPS cells) [75, 76].

If confirmed, the gene defect-independent and p53-dependent model mentioned above would explain why human genetic studies have constantly failed to identify gene variants specifically associated with the HSCR male bias [14]. Importantly, our finding that the negative impact of the putative p53-DDX3Y axis on ENCCs can be reversed by pharmacological means in mice also extends the list of potential mutation-independent preventive interventions for HSCR. Downregulating p53 activity during ENS development in utero might thus be considered an option for male fetuses in families with high genetic risk, just like the suggestion of avoiding nutritional deficiencies and high doses of specific medicines [77]. Considering that the vast majority of HSCR patients display aganglionosis over only a short segment of the distal colon [1, 2], such intervention might well be sufficient to prevent megacolon occurrence in many male individuals (up to 50% of them according to our human DDX3Y immunofluorescence data; Fig 2 and Table 1). While it is reasonable to believe that p53 inhibition increases tumorigenesis risk, this risk is minimized by the fact that such intervention would only need to be done over a relatively short period of time (i.e., for a maximum of 3–4 weeks, between weeks 4 to 7 of gestation). Alternatively, future work might help to identify a cellular stressor...
upstream of p53 that could also be pharmacologically targeted, as reported in a mouse model of Treacher-Collins syndrome [78].

**Materials and methods**

**Ethics statement**

Work with mice was approved by the Comité institutionnel de protection des animaux (CIPA reference #650 and #975) of Université du Québec à Montréal (UQAM), and performed in accordance with the guidelines of the Canadian Council on Animal Care (CCAC). For euthanasia, isoflurane-anesthetized mice were exposed to gradual-fill carbon dioxide.

Families of human participants provided written informed consent on studies, which were approved by the institutional human research ethics committees of the Université du Québec à Montréal (Comité institutionnel d’éthique de la recherche avec des êtres humains; protocol # 491) and the Centre hospitalier universitaire Sainte-Justine (Comité d’éthique à la recherche; protocol # 4172).

**Animals**

Heterozygous *Gata4p-GFP* and homozygous *TashT* transgenic lines were maintained and genotyped as previously described [29, 40]. *MycDdx3y* or *MycSry*-overexpressing mice were generated via standard pronuclear microinjection [79] into FVB/N zygotes. In each case, a *Tyrosinase* minigene [31] was co-injected to allow visual identification of transgenic animals via rescue of pigmentation [80], and homozygous animals were confirmed by backcrossing with wild-type FVB/N mice. For both *MycDdx3y* and *MycSry* transgenes, relevant coding sequences were subcloned in frame with an N-terminal Myc tag into an in house-modified pIRES2-EGFP vector (Clontech), where the CMV promoter was replaced by a synthetic promoter composed of the *Hsp68* minimal promoter [43] and neural crest-specific enhancers from *Sox10* (U3) [41] and *Ednrb* [42]. *Ddx3y* coding sequences and *Ednrb* regulatory sequences were amplified by RT-PCR and PCR, respectively, using nucleic acids from an e12.5 male FVB/N embryo, and then cloned in pGEM-T vector and fully sequenced to confirm the absence of PCR-caused mutations. The *domesticus Sry* cDNA (ORF and partial 3’ UTR), *Sox10 U3* enhancer, and *Hsp68* minimal promoter were subcloned from vectors kindly provided by Dr Chris Lau (University of California San Diego, USA), Dr Michael Wegner (Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany) and Dr Rashmi Kothary (Ottawa Hospital Research Institute, Canada), respectively.

For CRISPR/Cas9-mediated deletion at the *Hace1-Grik2* locus, double-stranded DNA oligonucleotides coding for top-scoring sgRNAs (as determined using the crispr.mit.edu tool) that flank the silencer-enriched region were cloned into the pX330 vector (Addgene plasmid # 42230; gift from Dr Feng Zhang) [81], and resulting constructs were used for in vitro transcription as previously described [82]. A mixture of Cas9 mRNA (100 ng/μl) and both sgRNAs (50 ng/μl each) was then prepared and used to microinject FVB/N zygotes, using conventional techniques [79]. Resulting *Hace1-Grik2*ΔSER mice were identified by PCR using primers located outside or within the deletion, and the exact nature of the deletion was determined by sequencing the amplicons generated with flanking primers. Details about all cloning and genotyping oligonucleotide primers can be found in S1 Table.

Embryos were obtained by timed pregnancies, with noon of the day of vaginal plug detection being considered e0.5. For in utero inhibition of p53, cyclic pifithrin-α hydrobromide (Sigma Cat.#P4236) was administered to pregnant *TashT*/*Tg* dams via intraperitoneal injections of a 0.4 mg/ml solution (in 2% DMSO-PBS) at a final concentration of 2 mg per kg of mouse body weight, as previously described [56]. Control animals were administered 2%
DMSO-PBS only. Dams were treated once a day (around noon) for a period of 7 days between e8.5 and e14.5, and embryos were collected at e15.5 for analysis.

**Sex-specific transcriptome profiling**

Ribosomal RNA-depleted RNA-seq libraries were both generated (from 300ng of total RNA) and sequenced by McGill University and Génomique Québec Innovation Centre using the HiSeq 2000 platform (Illumina). For both male and female \( TashT^{Tg/Tg} \) ENCCs, three biological replicates were generated from pools of e12.5 embryos, which were sexed based on morphological differences between male and female gonads. Cell dissociation of \( TashT^{Tg/Tg} \) bowel (stomach and small intestine), FACS-mediated recovery of ENCCs, and extraction of total RNA were all performed as previously described [29]. Paired-end sequences (100-bp in length; between 58–150 million reads per replicate) were mapped onto the mm10 *Mus musculus* reference genome, and analyzed for differential gene expression using DESeq and edgeR packages.

**RT-qPCR**

For quantitative RT-PCR analysis of ENCCs or transfected cell lines, cells of interest were recovered by FACS and their total RNA content was extracted as previously described [83]. Total RNA (100 ng per sample) was reverse transcribed using the Superscript III enzyme and a mixture of poly-dT18 and random primers, in accordance with the manufacturer’s instructions (ThermoFisher Scientific). 2 μl of the resulting cDNA pool was then used for amplification of the desired target using specific primers. Expression levels of the housekeeping gene *Psmrd2* were used for normalization. The qPCR program consisted of 45 cycles of 10 s at 95˚C and 30 s at 60˚C, with a melting curve from 65˚C to 95˚C. Relative expression was calculated with the 2-ΔΔCt method that refers to the ratio of the target genes to the housekeeping gene [84]. Details about qPCR primers can be found in S1 Table.

**Human studies**

Human specimens of ENS-containing sigmoid colon (corresponding to the “transition” zone) were obtained from two different HSCR cohorts without genetic information. The first cohort is described in Soret *et al.* [32] as the HSCR case group (n = 12; 10 boys and 2 girls; aged between 17 and 454 days at the time of surgery). The second cohort was constituted from four patients (4 boys; aged between 22 and 349 days at the time of surgery) who underwent surgical resection at the Centre hospitalier universitaire Sainte-Justine (Montreal, Canada). Details for each analyzed tissue are displayed in Table 1. Tissues were processed for immunofluorescence as previously described [32], using mouse monoclonal anti-DDX3Y (Sigma Cat. #WH0008653M1; dilution factor 1/500) and guinea pig polyclonal anti-PGP9.5 (Neuromics Cat.#GP14104; dilution factor 1/100) antibodies.

**4C-seq and 3C-PCR**

4C-seq was performed essentially as previously described [46], with slight modifications to accommodate limited starting material (1x10^6 FACS-recovered ENCCs per sample) and a different sequencing platform for longer reads (Ion PGM; ThermoFisher Scientific). For each sample, captured chromatin fragments were reduced in size by sonication using an E220 Focused-ultrasonicator (Covaris) set with a peak power of 175, a duty factor of 10%, and 200 cycles for 45 seconds. Sequencing libraries were prepared using the Ion Xpress Plus Fragment Library Kit and the gDNA Fragment Library Preparation protocol (ThermoFisher Scientific Cat.#MAN0009847). Sequencing particles were generated with the Ion PGM Hi-Q Chef Kit.
(ThermoFisher Scientific Cat.#MAN0010919), and sequencing was performed on Ion 318 Bar-coded chips adapted for sequencing fragments of 400 bp or less (ThermoFisher Scientific Cat.#4488146). The 4C-seq analysis was performed using two biological replicates per group. All data from both replicates were kept for further analysis, recognizing that chromatin contacts are often transitory [85] and most especially during development [86, 87]. Sequencing data were then analyzed using the w4Cseq pipeline [47], which was modified to accommodate long single reads instead of short paired-end reads. Genes associated with captured fragments were identified using the Table Browser tool from the UCSC Genome Browser (genome.ucsc.edu).

3C-PCR was performed as previously described [29], using primers listed in S1 Table.

**Staining of developing and postnatal murine ENS**

Staining of AChE activity in postnatal colon and whole-mount immunofluorescence staining of e12.5 bowel tissues were both performed using standard approaches, as previously described [32, 88]. Antibodies used for whole-mount immunofluorescence included mouse monoclonal anti-βIII-Tubulin clone 2G10 (Abcam Cat.#ab78078; dilution factor 1:500), rabbit polyclonal anti-GFP (Abcam Cat.#Ab290; dilution factor 1:500) and rat polyclonal anti-SOX10 (generated by MediMabs for the Pilon lab; dilution factor 1:500). Analysis of endogenous YFP fluorescence in unfixed freshly dissected e15.5 TashT<sup>TGf/TGf</sup> colons was performed as previously described [29]. For p53 and Myc tag immunofluorescence in dissociated tissues, acute cultures of e12.5 bowel were prepared and stained essentially as previously described [83]. Briefly, for each tested embryo, dissected stomach and small intestine were dissociated in 100 μL of EMEM containing collagenase (0.4 mg/ml; Sigma Cat.#C2674), dispase II (1.3 mg/ml; ThermoFisher Scientific Cat.#17105–041) and DNAse I (0.5 mg/ml; Sigma Cat.#DN25) at 37˚C. Cells were then centrifuged at 300g for 3 minutes, resuspended in 200 μl of EMEM with 10% FBS on a μ-slide 8-well Ibireat plate (Ibidi 80826) coated with fibronectin (250 μg/ml; EMD Millipore Cat.#FC010), and incubated at 37˚C with 5% CO2 for 4 to 6 hours. Cells were finally fixed for 10 minutes in 4% PFA on ice, and processed for immunofluorescence with mouse monoclonal anti-p53 (Cell Signaling Cat.#2524; dilution factor 1:250), rabbit polyclonal anti-GFP (Abcam Cat #Ab290; dilution factor 1:500), mouse monoclonal anti-Myc tag (In house hybridoma clone 9E10; dilution factor 1:100) and/or rat polyclonal anti-SOX10 (generated by MediMabs for the Pilon lab; dilution factor 1:500).

**Cell culture and transfections**

Neuro2a neuroblastoma cells, F9 embryocarcinoma cells, P19 embryocarcinoma cells, and R1 embryonic stem cells were maintained and propagated as previously described [88, 90]. To evaluate the activity of <sup>My</sup>DDx3y-IRES-eGFP and <sup>My</sup>Sry-IRES-eGFP transgenic constructs, 3x10<sup>5</sup> Neuro2a cells were seeded in 6-well plates containing coverslips and transfected with Genejuice reagents (Novagen) in accordance with manufacturer’s instructions. Coverslips were then used to analyze transfected cells for co-expression of eGFP and Myc-tagged proteins via anti-Myc immunofluorescence (mouse monoclonal Myc tag antibody clone 9E10; in house hybridoma; dilution factor 1:100). To evaluate the importance of p53 in the regulation of Ddx3x and Ddx3y gene expression, male cell lines (F9, P19 and R1) were seeded in 100mm plates (1x10<sup>6</sup> to 2x10<sup>6</sup> cells) and transfected with either p53 (stealth siRNA Trp53; Cat. #1320001, MSS212108; ThermoFisher Scientific) or negative control (stealth RNAi siRNA negative control; Cat.#12935300 Med GC; ThermoFisher Scientific) siRNAs using jetPRIME reagents (Cat.#114–75; Polyplus transfection) in accordance with the manufacturer’s instructions. Each siRNA (30nM) was co-transfected with empty pIRES2-EGFP plasmid (10μg; Clontech), and transfected cells (EGFP+) were then recovered by FACS 48h later and processed for...
RT-qPCR analysis of p53, Ddx3x and Ddx3y gene expression. Primer details can be found in S1 Table.

**Image acquisition and processing**

Images were acquired either with a Leica M205 FA stereomicroscope equipped with a Leica DFC 495 camera (for staining of AChE activity in postnatal colon tissues and fluorescence imaging in whole embryos) or a Nikon A1 laser scanning confocal microscope (for fluorescence imaging in general). Image processing and analysis was all done with the ImageJ software.

**ChIP analysis**

ChIP assays in R1 embryonic stem cells were performed as previously described [83], using a mouse monoclonal p53 antibody (Cell Signaling #2524; dilution factor 1:200). To activate p53, R1 cells were subjected to a transfection stress prior to ChIP, by transfecting the empty pIRE-S2-EGFP vector as described above for siRNA analyses. Occupation of p53 binding sites from Ddx3y, Ddx3x and Mdm2 promoters in control and stressed R1 cells was determined by qPCR, using the program described in the RT-qPCR section. ChIP efficiency was calculated by comparison of input-normalized values (in %) obtained with stressed vs control cells. PCR-amplified regions containing p53 binding sites were determined based on the literature [51] and a MatInspector analysis (www.genomatix.de) for the Ddx3x and Ddx3y promoters, or the literature only [55] for the Mdm2 promoter.

**Statistics**

Where applicable, data are presented as mean ± standard deviation, with the number of biological replicates indicated in figures and/or legends. Student’s t-test (two-tailed) was used to determine statistical significance, using 0.05 as cut-off value for P. Numerical data and statistics for all graphs can be found in S2 Table.

**Supporting information**

**S1 Fig. Characterization of the p53, Ddx3x and Ddx3y gene expression.**

(A) Complete sequence of the Ednrb-Sox10-Hsp68 synthetic promoter. Restriction sites used for cloning are in lowercase letters. (B) Schematic representation of the p53, Ddx3x and Ddx3y transgenic construct, with regulatory sequences in grey. (C) Immunofluorescence labeling of Neuro2a cells transfected with the p53, Ddx3x and Ddx3y transgenic construct and showing co-expression of p53, Ddx3x and Ddx3y proteins. Scale bar, 10μm. (D) RT-qPCR analysis of p53, Ddx3x and Ddx3y gene expression in e12.5 TashT\textsuperscript{Tg/+};\(p53^{+/+}\) ENCCs recovered by FACS. (E) Detailed quantitative analysis of the length of ENS-covered colon (in % of total colon length) in P18-P50 TashT\textsuperscript{Tg/+} mice bearing or not a transgenic allele from each of the three p53, Ddx3x and Ddx3y transgenic lines. Every p53, Ddx3x and Ddx3y transgenic line is identified using the same color code as in Fig 1E and 1F. The dashed lines show the previously described threshold level interval above which megacolon is less likely to occur in FVB/N mice [29]. (*P≤0.05; **P≤0.01; Student’s t-test).

(TIF)

**S2 Fig. Detection of Ddx3x and Ddx3y protein in e12.5 midgut cells dissociated from TashT\textsuperscript{Tg/+}; Ddx3x\textsuperscript{Tg/+} embryos.**

Representative confocal images of e12.5 midgut cells dissociated from TashT\textsuperscript{Tg/+} control and TashT\textsuperscript{Tg/+}; p53\textsuperscript{Tg/+}; Ddx3x\textsuperscript{Tg/+} (line 3) embryos, and immunolabeled for SOX10 (red) and Myc tag (grey). ENCCs are endogenously labeled with YFP owing to the
pSRY[p1.6kb]-YFP transgene in the TashT line. Scale bar, 20 μm.

S3 Fig. Overexpression of either Myc-Ddx3y or Myc-Sry has no impact on ENS patterning. Representative images of proximal colon tissues collected from P18-50 TashT^{Tg/+} mice bearing or not Myc-Ddx3y or Myc-Sry transgenic constructs and stained for AChE activity. Scale bar, 1000 μm.

S4 Fig. Overexpression of Myc-Ddx3y, but not Myc-SRY, worsens extent of aganglionosis in TashT^{Tg/Tg} males. Representative images of P18-50 colon tissues collected from male mice and stained for AChE activity. Corresponding quantitative analyses are shown in Fig 1E and 1G. Scale bar, 1000 μm.

S5 Fig. Overexpression of either Myc-Ddx3y or Myc-SRY has no impact on extent of aganglionosis in TashT^{Tg/Tg} females. Representative images of P18-50 colon tissues collected from female mice and stained for AChE activity. Corresponding quantitative analyses are shown in Fig 1F and 1H. Scale bar, 1000 μm.

S6 Fig. Characterization of the Myc-Sry transgenic mouse line. (A) Schematic representation of the Myc-Sry-IRES-eGFP transgenic construct, with regulatory sequences in grey. (B) Immunofluorescence labeling of Neuro2a cells transfected with the Myc-Sry-IRES-eGFP transgenic construct and showing co-expression of Myc-SRY (red) and GFP (green) proteins. Scale bar, 10μm. (C) Representative image of GFP-labeled neural crest-derived cells in e11.5 Myc-Sry-IRES-eGFP transgenic embryos (n = 12). Left panels show GFP labeling of cranial nerves and dorsal root ganglia. Right panel is a high magnification view of the gut, to show GFP labeling of ENCCs in the prospective stomach (St) and small intestine (SI). Scale bar, 1000 μm (left panel); 200 μm (Right panel).

S7 Fig. Activity of the Ednrb-Sox10U3-Hsp68 synthetic promoter in ENCCs. (A-B) Representative confocal images of e12.5 midguts collected from Myc-Sry^{Tg/+} embryos and immunolabelled for SOX10 (red), βIII-Tubulin (grey), GFP (green) and DAPI (blue). High magnification views shown in B are delineated by dashed square in A. As evidenced on both x-y and x-z planes, GFP signal is mainly present in SOX10^{+} cells. (C) Quantification of the number of SOX10^{+} GFP^{+} double positive cells on the total number of SOX10^{+} cells. The total number of counted cells is indicated in brackets. Scale bar, 50 μm (A) and 20μM (B).

S8 Fig. Selection of the best primer pair for the 4C-seq analysis. (A) Genomic representation of the Hace1-Grik2 intergenic region on chromosome 10, using the UCSC genome browser (genome.ucsc.edu) and its vertebrate Multiz Alignment & Conservation tract. Conserved elements (CE) are indicated by either black (neutral activity) or red (silencer activity) boxes, based on transcriptional activity in luciferase assays previously performed in Neuro2a and P19 cell lines [29]. Position of 4C-seq primer pairs is illustrated in blue (1), yellow (2), purple (3), green (4), and pink (5). (B) A test 4C-library was prepared using Neuro2a cells and used to evaluate efficiency of each primer pairs. The third pair (purple) was selected based on PCR profile and proximity to silencer elements.
S9 Fig. The colon of Hace1-Grik2ΔSER/ΔSER embryos is normally colonized by ENCCs. (A) Representative images of P18-50 proximal colon tissues collected from wild-type (WT; FVB/N control) and Hace1-Grik2ΔSER/ΔSER (ΔSER/ΔSER) mice, and stained for AChE activity. Lower magnification images are displayed in Fig 3C. (B) Quantitative analysis of the extent of colon colonization by βIII-Tubulin⁺ ENCCs (in % of total colon length) in WT and Hace1--Grik2ΔSER/ΔSER e12.5 embryos, showing normal colonization in mutant animals. Representative images are shown is Fig 3D. Scale bar, 1000 μm.

(TIF)

S10 Fig. Sexing of Neuro2a cell line. (A) PCR-based sexing of Neuro2a cells showing the presence of the X-linked gene SmcX (300 pb) but the absence of Y-linked genes Zfy (420 pb) and Smcy (280 pb). Genomic DNA from female (F) or male (M) mice was used as controls. (B) Relative expression of Psmd2 (autosomal gene), Ddx3x (X-linked gene) and Ddx3y (Y-linked gene) in Neuro2a compared to a known male mouse cell line (P19). Normalization to Psmd2 expression reveal the absence of Ddx3y expression.

(TIF)

S1 Table. List of all primers used in this study. Full sequence of all oligonucleotides used in this study is shown in the 5’ to 3’ orientation. The purpose for which oligonucleotides were used is also mentioned.

(PDF)

S2 Table. Numerical data and statistics for all graphs. Each graph has its own tab.

(XLSX)

S1 Dataset. Differential gene expression in male vs female TashTmTg ENCCs (>1.5-fold change; P≤0.05; minimum of 250 reads in at least one condition).

(XLSX)

S2 Dataset. Differential gene expression in TashTmTg vs Gata4p-GFP control ENCCs (>1.5-fold change; P≤0.05; minimum of 250 reads in at least one condition).

(XLSX)

S3 Dataset. List of all loci and associated genes captured by 4C-seq. Each sample has its own tab.

(XLSX)

S4 Dataset. Lists of genes for all Venn diagram categories displayed in Fig 4A. Each category has its own tab.

(XLSX)

Acknowledgments

The authors thank Normand Lapierre and Guillaume Bernas (Transgenesis core, CERMO-FC, UQAM) for the production of genetically-modified mice, Denis Flipo (Cellular analyses core, CERMO-FC, UQAM) for assistance with confocal imaging and cell sorting, Geneviève Bourret (Genomics core, CERMO-FC, UQAM) for assistance with preparation of 4C-seq libraries, Golrokh Kiani (Bioinformatics core, CERMO-FC, UQAM) for assistance with analysis of 4C-seq data, as well as Dr Ann Aspirot and Dr Natalie Patey for access to human samples (CHU Ste-Justine). The Massively parallel sequencing platform as well as the Bioinformatics platform of the McGill University and Génome Québec Innovation Center are also thanked for transcriptome sequencing and analyses of sequencing results, respectively. Likewise, the Genomics platform of the Centre de recherche du Centre Hospitalier Universitaire Sainte-Justine as well
as the Bioinformatics platform of the Institut de Recherches en immunologie et en cancérologie (IRIC) are thanked for sequencing and analyses of 4C-seq libraries, respectively. The Genomics core facility at the Sunnybrook research institute is also thanked for the second round of sequencing of 4C-seq libraries.

**Author Contributions**

**Conceptualization:** Nicolas Pilon.

**Formal analysis:** Tatiana Cardinal, Karl-Frédéric Bergeron, Nicolas Pilon.

**Funding acquisition:** Nicolas Pilon.

**Investigation:** Tatiana Cardinal, Karl-Frédéric Bergeron, Ouliana Souchkova, Améline Guillon.

**Methodology:** Tatiana Cardinal.

**Resources:** Rodolphe Soret, Christophe Faure.

**Supervision:** Nicolas Pilon.

**Writing – original draft:** Tatiana Cardinal, Nicolas Pilon.

**Writing – review & editing:** Karl-Frédéric Bergeron, Nicolas Pilon.

**References**

1. Amiel J, Sproat-Ermon E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, et al. Hirschprung disease, associated syndromes and genetics: a review. J Med Genet. 2008; 45(1):1–14. Epub 2007/10/30. jmg.2007.053959 [pii] https://doi.org/10.1136/jmg.2007.053959 PMID: 17965226.

2. Heuckeroth RO. Hirschsprung disease—integrating basic science and clinical medicine to improve outcomes. Nat Rev Gastroenterol Hepatol. 2018; 15(3):152–67. https://doi.org/10.1038/nrgastro.2017.149 PMID: 29300049.

3. Pini Prato A, Gentilino V, Giunta C, Avanzini S, Mattioli G, Parodi S, et al. Hirschsprung disease: do risk factors of poor surgical outcome exist? J Pediatr Surg. 2008; 43(4):612–9. Epub 2008/04/15. https://doi.org/10.1016/j.jpedsurg.2007.05.007 PMID: 18405705.

4. Bergeron KF, Silversides DW, Pilon N. The developmental genetics of Hirschsprung’s disease. Clin Genet. 2013; 83(1):15–22. Epub 2012/10/10. https://doi.org/10.1111/cge.12032 PMID: 23043324.

5. Nagy N, Goldstein AM. Enteric nervous system development: A crest cell’s journey from neural tube to colon. Semin Cell Dev Biol. 2017; 66:94–106. Epub 2017/01/15. https://doi.org/10.1016/j.semcdb.2017.01.006 PMID: 28087321; PubMed Central PMCID: PMC5474363.

6. Rao M, Gershon MD. Enteric nervous system development: what could possibly go wrong? Nat Rev Neurosci. 2018; 19(9):552–65. Epub 2018/07/27. https://doi.org/10.1038/s41583-018-0041-0 PMID: 30046054.

7. Yntema CL, Hammond WS. The origin of intrinsic ganglia of trunk viscera from vagal neural crest in the chick embryo. J Comp Neurol. 1954; 101(2):515–41. Epub 1954/10/01. PMID: 13221667.

8. Espinosa-Medina J, Jevans B, Boismoreau F, Chettouh Z, Enomoto H, Muller T, et al. Dual origin of enteric neurons in vagal Schwann cell precursors and the sympathetic neural crest. Proc Natl Acad Sci U S A. 2017; 114(45):11980–5. Epub 2017/10/29. https://doi.org/10.1073/pnas.1710308114 PMID: 29078343; PubMed Central PMCID: PMC5692562.

9. Le Douarin NM, Teillet MA. The migration of neural crest cells to the wall of the digestive tract in avian embryo. Journal of embryology and experimental morphology. 1973; 30(1):31–48. Epub 1973/08/01. PMID: 4729950.

10. Uesaka T, Nagashimada M, Enomoto H. Neuronal Differentiation in Schwann Cell Lineage Underlies Postnatal Neurogenesis in the Enteric Nervous System. J Neurosci. 2015; 35(27):9879–88. https://doi.org/10.1523/JNEUROSCI.1239-15.2015 PMID: 26156989.

11. Burn A, Champeval D, Le Douarin NM. Sacral neural crest cells colonise aganglionic hindgut in vivo but fail to compensate for lack of enteric ganglia. Dev Biol. 2000; 219(1):30–43. PMID: 10677253.
12. Tang CSM, Zhuang X, Lam W-Y, Ngan ES-W, Hsu JS, Michelle YU, et al. Uncovering the genetic lesions underlying the most severe form of Hirschsprung disease by whole-genome sequencing. European Journal of Human Genetics. 2018; 26(6):818–26. https://doi.org/10.1038/s41375-018-0129-z
13. Tang CS-m, Li P, Lai FP-L, Fu AX, Lau S-T, So MT, et al. Identification of genes associated with Hirschsprung disease, based on whole-genome sequence analysis, and potential effects on enteric nervous system development. Gastroenterology. 2018; 155(6):1908–22.e5. https://doi.org/10.1053/j.gastro.2018.09.012.
14. Tlighman JM, Ling AY, Turner TN, Sosa MX, Krumm N, Chatterjee S, et al. Molecular genetic anatomy and risk profile of Hirschsprung's disease. New England Journal of Medicine. 2019; 380(15):1421–32. https://doi.org/10.1056/NEJMoa1706594
15. Gui H, Schriemer D, Cheng WW, Chauhan RK, Antitholo G, Berrios C, et al. Whole exome sequencing coupled with unbiased functional analysis reveals new Hirschsprung disease genes. Genome Biology. 2017; 18(1):48. https://doi.org/10.1186/s13059-017-1174-6
16. Cantrell VA, Owens SE, Chandler RL, Airey DC, Bradley KM, Smith JR, et al. Interactions between Sox10 and Ednrb modulate penetrance and severity of aganglionosis in the Sox10Dom mouse model of Hirschsprung disease. Hum Mol Genet. 2004; 13(19):2289–301. https://doi.org/10.1093/hmg/ddh243 PMID: 15294878.
17. Dang R, Torigoe D, Suzuki S, Kikkawa Y, Moritoh K, Sasaki N, et al. Genetic background strongly modifies the severity of symptoms of Hirschsprung disease, but not hearing loss in rats carrying Ednrb(sl) mutations. PLoS ONE. 2011; 6(9):e24086. Epub 2011/09/15. https://doi.org/10.1371/journal.pone.0024086 PMID: 21915282; PubMed Central PMCID: PMC3168492.
18. McCallion AS, Stames E, Conlon RA, Chakravarti A. Phenotype variation in two-locus mouse models of Hirschsprung disease: tissue-specific interaction between Ret and Ednrb. Proc Natl Acad Sci U S A. 2003; 100(4):1826–31. PMID: 12574515.
19. Uesaka T, Nagashimada M, Yonemura S, Enomoto H. Diminished Ret expression compromises neuronal survival in the colon and causes intestinal aganglionosis in mice. J Clin Invest. 2008; 118(5):1890–8. Epub 2008/04/17. https://doi.org/10.1172/JCI34425 PMID: 18414682; PubMed Central PMCID: PMC2293334.
20. Vohra BP, Planer W, Armon J, Fu M, Jain S, Heuckeroth RO. Reduced endothelin converting enzyme-1 and endothelin-3 mRNA in the developing bowel of male mice may increase expressivity and penetrance of Hirschsprung disease-like distal intestinal aganglionosis. Dev Dyn. 2007; 236(1):106–17. https://doi.org/10.1002/dvdy.21028 PMID: 17131407.
21. Okamoto N, Del Maestro R, Valero R, Monros E, Poo P, Kanemura Y, et al. Hydrocephalus and Hirschsprung’s disease with a mutation of L1CAM. J Hum Genet. 2004; 49(6):334–7. Epub 2004/05/19. https://doi.org/10.1007/s10038-004-0153-4 PMID: 15148591.
22. Parisi MA, Kapur RP, Neilson I, Hofstra RM, Holloway LW, Michaelis RC, et al. Hydrocephalus and intestinal aganglionosis: is L1CAM a modifier gene in Hirschsprung disease? Am J Med Genet. 2002; 106(1):51–6. Epub 2002/02/22. https://doi.org/10.1002/ajmg.10185 [pii]. PMID: 11857550.
23. Fransen E, Lemmon V, Van Camp G, Vits L, Coucke P, Willems PJ. CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1CAM. J Hum Genet. 1995; 3(5):273–84. Epub 1995/01/01. PMID: 8556302.
24. Wallace AS, Tan MX, Schachner M, Anderson RB. L1cam acts as a modifier gene for members of the endothelin signalling pathway during enteric nervous system development. Neurogastroenterol Motil. 2011; 23(11):e510–22. Epub 2011/03/15. https://doi.org/10.1111/j.1365-2982.2011.01692.x PMID: 21395909.
25. Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R. Male development of chromosomally female mice transgenic for Sry. Nature. 1991; 351(6322):117–21. Epub 1991/05/09. https://doi.org/10.1038/351117a0 PMID: 2030730.
26. Lee J, Harley VR. The male fight-flight response: A result of SRY regulation of catecholamines? BioEssays. 2012; 34(6):454–7. https://doi.org/10.1002/bies.201100159
27. Lee J, Pinares-Garcia P, Loke H, Sam S, Vilain E, Harley VR. Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson's disease. Proc Natl Acad Sci U S A. 2019. Epub 2019/08/03. https://doi.org/10.1073/pnas.1900406116 PMID: 31371505.
28. Boyer A, Plon N, Raitt DL, Lussier JG, Silversides DW. Human and pig SRY 5' flanking sequences can direct reporter transgene expression to the genital ridge and to migrating neural crest cells. Dev Dyn. 2006; 235(3):623–32. PMID: 16411204.
29. Bergeron KF, Cardinal T, Toure AM, Beland M, Raitt DL, Silversides DW, et al. Male-Biased Aganglionic Megacolon in the TashT Mouse Line Due to Perturbation of Silencer Elements in a Large Gene.
Desert of Chromosome 10. PLoS Genet. 2015; 11(3):e1005093. https://doi.org/10.1371/journal.pgen.1005093 PMID: 25786024.

30. Li Y, Kido T, Garcia-Barcelo MM, Tam PK, Tabatabai ZL, Lau YF. SRY interference of normal regulation of the RET gene suggests a potential role of the Y-chromosome gene in sexual dimorphism in Hirschsprung disease. Hum Mol Genet. 2015; 24(3):685–97. https://doi.org/10.1093/hmg/ddu488 PMID: 25267720; PubMed Central PMCID: PMC4291247.

31. Bergeron KF, Nguyen CM, Cardinal T, Charrier B, Silversides DW, Pilon N. Upregulation of the Nr2f1-A830082K12Rik gene pair in murine neural crest cells results in a complex phenotype reminiscent of waardenburg syndrome type 4. Disease models & mechanisms. 2016; 9(11):1283–93. Epub Sep 1. https://doi.org/10.1016/j.dmm.026773 PMID: 27585883.

32. Soret R, Mennetrey M, Bergeron KF, Dariel A, Neunlist M, Grunder F, et al. A collagen VI-dependent pathogenic mechanism for Hirschsprung’s disease. J Clin Invest. 2015; 125(3):4485–96. https://doi.org/10.1172/JCI83178 PMID: 25267720.

33. Cheng LS, Schwartz DM, Hotta R, Graham HK, Goldstein AM. Bowel dysfunction following pullthrough surgery is associated with an overabundance of nitrosergic neurons in Hirschsprung disease. J Pediatr Surg. 2016; 51(11):1234–8. https://doi.org/10.1016/j.jpedsurg.2016.08.001 PMID: 27570241; PubMed Central PMCID: PMC4291247.

34. Toure AM, Charrier B, Pilon N. Male-specific colon motility dysfunction in the TashT mouse line. Neurogastroenterol Motil. 2016; 28(10):1494–507. https://doi.org/10.1111/nmo.12487 PMID: 27278627.

35. Zaitoun I, Erickson CS, Barlow AJ, Klein TR, Heneghan AF, Pierre JF, et al. Altered neuronal density and neurotransmitter expression in the ganglionated region of Ednrb null mice: implications for Hirschsprung’s disease. Neurogastroenterol Motil. 2013; 25(3):e233–44. https://doi.org/10.1111/nmo.12083 PMID: 23360229; PubMed Central PMCID: PMC3578114.

36. Pierre JF, Barlow-Anacker AJ, Erickson CS, Heneghan AF, Leversen GE, Dowd SE, et al. Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung’s disease. J Pediatr Surg. 2014; 49(8):1242–51. https://doi.org/10.1016/j.jpedsurg.2014.01.060 PMID: 25092084; PubMed Central PMCID: PMC4122863.

37. Toure AM, Landry M, Souchkova O, Kembel SW, Pilon N. Gut microbiota-mediated Gene-Environment interaction in the TashT mouse model of Hirschsprung disease. Scientific reports. 2019; 9(1):492. Epub 2019/01/27. https://doi.org/10.1038/s41598-018-36967-z PMID: 30679567.

38. Ward NL, Pieretti A, Dowd SE, Cox SB, Goldstein AM. Intestinal aganglionosis is associated with early and sustained disruption of the colonic microbiome. Neurogastroenterol Motil. 2012; 24(9):e374–e400. https://doi.org/10.1111/j.1365-2982.2012.01937.x PMID: 22626027.

39. Pilon N. Pigmentation-based insertional mutagenesis is a simple and potent screening approach for identifying neurocristopathy-associated genes in mice. Rare Diseases. 2016; 4(1):e1156287. Epub 2016/03/20.

40. Pilon N, Raiwat D, Viger RS, Silversides DW. Novel pre- and post-gastrulation expression of Gata4 within cells of the inner cell mass and migratory neural crest cells. Dev Dyn. 2008; 237(4):1133–43. PMID: 18351674.

41. Werner T, Hammer A, Wahlihui M, Bosi MR, Wegner M. Multiple conserved regulatory elements with overlapping functions determine Sox10 expression in mouse embryogenesis. Nucleic Acids Res. 2007; 35(19):e52–38. PMID: 17897962.

42. Zhu L, Lee HO, Jordan CS, Cantrell VA, Southard-Smith EM, Shin MK. Spatiotemporal regulation of endothelin receptor-B by SOX10 in neural crest-derived enteric neuron precursors. Nat Genet. 2004; 36(7):732–7. Epub 2004/06/01. https://doi.org/10.1038/ng1371 PMID: 15170213.

43. Kothary R, Clapoff S, Darling S, Perry MD, Moran LA, Rossant J. Inducible expression of an hsp68-lacZ hybrid gene in transgenic mice. Development. 1989; 105(4):707–14. Epub 1989/04/01. PMID: 2557196.

44. Pilon N, Raiwat D, Viger RS, Silversides DW. Novel pre- and post-gastrulation expression of Gata4 within cells of the inner cell mass and migratory neural crest cells. Dev Dyn. 2008; 237(4):1133–43. PMID: 18351674.

45. Vakilian H, Mirzaei M, Sharifi Tabar M, Pooyan P, Habibi Rezaee L, Parker L, et al. DDX3Y, a Male-Specific Region of Y Chromosome Gene, May Modulate Neuronal Differentiation. Journal of proteome research. 2015; 14(9):3474–83. Epub 2015/07/07. https://doi.org/10.1021/acs.jproteome.5b00512 PMID: 26144214.

46. Poulat F, Girard F, Chevron MP, Goze C, Rebillard X, Calas B, et al. Nuclear localization of the testis determining gene product SRY. The Journal of cell biology. 1995; 128(5):737–48. Epub 1995/03/01. https://doi.org/10.1083/jcb.128.5.737 PMID: 7876301; PubMed Central PMCID: PMC2120386.

47. van de Werken HUG, de Vree PJP, Splinter E, Holwerda SJH, Klous P, de Wit E, et al. Chapter four - 4C technology: Protocols and data analysis. In: Wu C, Allis CD, editors. Methods in Enzymology: Nucleosomes, Histones & Chromatin Part B. 513. USA, UK & The Netherlands: Academic Press; 2012. p. 89–112.
47. Cai M, Gao F, Lu W, Wang K. w4CSeq: software and web application to analyze 4C-seq data. Bioinformatics 2016; 32(21):3333–5. Epub 2016/07/04. https://doi.org/10.1093/bioinformatics/btw408 PMID: 27378289.

48. Shang X, Vasudevan SA, Yu Y, Ge N, Ludwig AD, Wesson CL, et al. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene. 2010; 29(35):4938–46. https://doi.org/10.1038/onc.2010.244 PMID: 20562916.

49. Lokareddy RK, Bhardwaj A, Cingolani G. Atomic structure of dual-specificity phosphatase 26, a novel p53 phosphatase. Biochemistry. 2013; 52(5):938–48. https://doi.org/10.1021/bi301476m

50. Shi Y, Ma IT, Patel RH, Shang X, Chen Z, Zhao Y, et al. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis. Cell Death Dis. 2015; 6:e1841. Epub 2015/08/08. https://doi.org/10.1038/cddis.2015.207 PMID: 26247726; PubMed Central PMCID: PMC4558500.

51. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(7):1895–905. https://doi.org/10.1158/1078-0432.CCR-10-2316 PMID: 21325288.

52. Wu DW, Lee MC, Wang J, Chen CY, Cheng YW, Lee H. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene. 2014; 33(12):1515–26. https://doi.org/10.1038/onc.2013.107 PMID: 23984477.

53. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323–31. Epub 1997/02/07. https://doi.org/10.1016/s0092-8674(00)81871-1 PMID: 9039529.

54. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003; 15(2):164–71. Epub 2003/03/22. https://doi.org/10.1016/s0955-0674(03)00036-6 PMID: 12648672.

55. Mendrysa SM, Perry ME. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol. 2000; 20(6):2023–30. Epub 2000/02/25. https://doi.org/10.1128/mcb.20.6.2023–2030.2000 PMID: 1068649; PubMed Central PMCID: PMC110819.

56. Jones NC, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey JP, et al. Prevention of the neurocris tophy Treacher Collins syndrome through inhibition of p53 function. Nat Med. 2008; 14(2):125–33. Epub 2008/02/05. nm1725 [pii] https://doi.org/10.1038/nm1725 PMID: 18246078; PubMed Central PMCID: PMC3093709.

57. Kido T, Sun Z, Lau YC. Aberrant activation of the human sex-determining gene in early embryonic development results in postnatal growth retardation and lethality in mice. Scientific reports. 2017; 7(1):4113. Epub 2017/06/25. https://doi.org/10.1038/s41598-017-04117-6 PMID: 28646221; PubMed Central PMCID: PMC5482865.

58. Santos SF, de Oliveira HL, Yamada ES, Neves BC, Pereira A Jr. The Gut and Parkinson’s Disease -A Bidirectional Pathway. Front Neurol. 2019; 10:574. Epub 2019/06/20. https://doi.org/10.3389/fneur.2019.00574 PMID: 31214110; PubMed Central PMCID: PMC6552910.

59. Czech DP, Lee J, Sim H, Parish CL, Vilain E, Harley VR. The human testis-determining factor SRY localizes in midbrain dopamine neurons and regulates multiple components of catecholamine synthesis and metabolism. J Neurochem. 2012; 122(2):250–71. Epub 2012/05/10. https://doi.org/10.1111/j.1471-4159.2012.07782.x PMID: 22586433; PubMed Central PMCID: PMC3529967.

60. Dilton HJ, Zimmer J, Kamp C, Rajpert-De Meyts E, Vogt PH. The AZFa gene DBY (DDX3Y) is widely transcribed but the protein is limited to the male germ cells by translation control. Hum Mol Genet. 2004; 13(19):2333–41. Epub 2004/08/06. https://doi.org/10.1093/hmg/ddh240 PMID: 15294876.

61. Rosinski KV, Fuji N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood. 2008; 111(9):4817–26. Epub 2008/02/27. https://doi.org/10.1182/blood-2007-06-096313 PMID: 18299450; PubMed Central PMCID: PMC2343610.

62. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science. 2015; 350(6264):1096–101. Epub 2015/10/17. https://doi.org/10.1126/science.aac7041 PMID: 26472758; PubMed Central PMCID: PMC4662922.

63. Fuller-Pace FV. DEAD box RNA helicase functions in cancer. RNA biology. 2013; 10(1):121–32. Epub 2013/01/29. https://doi.org/10.4161/ma.23312 PMID: 23353573; PubMed Central PMCID: PMC3590229.

64. He Y, Zhang D, Yang Y, Wang X, Zhao X, Zhang P, et al. A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression (Review). Oncol Rep. 2018; 39(3):883–92. Epub 2018/01/13. https://doi.org/10.3892/or.2018.6203 PMID: 29328432.
65. Sekiguchi T, Iida H, Fukumura J, Nishimoto T. Human DDX3Y, the Y-encoded isoform of RNA helicase DDX3X, rescues a hamster temperature-sensitive ET24 mutant cell line with a DDX3X mutation. Experimental cell research. 2004; 300(1):213–22. Epub 2004/09/24. https://doi.org/10.1016/j.yexcr.2004.07.005 PMID: 15383328.

66. Szappanos D, Tschismarow R, Perlot T, Westernayer S, Fischer K, Plataniotis E, et al. The RNA helicase DDX3X is an essential mediator of innate antimicrobial immunity. PLoS Pathog. 2018; 14(11): e1007397. Epub 2018/11/27. https://doi.org/10.1371/journal.ppat.1007397 PMID: 30475900; PubMed Central PMCID: PMC6283616.

67. Foresta C, Ferlin A, Moro E. Deletion and expression analysis of AZFa genes on the human Y chromosome revealed a major role for DBY in male infertility. Hum Mol Genet. 2000; 9(8):1161–9. Epub 2000/04/18. https://doi.org/10.1093/hmg/9.8.1161 PMID: 10767340.

68. Deng X, Berletch JB, Nguyen DK, Distorch CM. X chromosome regulation: diverse patterns in development, tissues and disease. Nat Rev Genet. 2014; 15(6):367–78. https://doi.org/10.1038/nrg3687 PMID: 24733023.

69. Geissler R, Golbik RP, Behrens SE. The DEAD-box helicase DDX3 supports the assembly of functional 80S ribosomes. Nucleic Acids Res. 2012; 40(11):4998–5011. Epub 2012/02/11. https://doi.org/10.1093/nar/gks070 PMID: 22323517; PubMed Central PMCID: PMC3367175.

70. Mazeyrat S, Saut N, Grigoriev V, Mahadevaiah SK, Ojairkire OA, Rattingan A, et al. A Y-encoded subunit of the translation initiation factor eIF2 is essential for mouse spermatogenesis. Nat Genet. 2001; 29(1):49–53. Epub 2001/08/31. https://doi.org/10.1093/nig/117 PMID: 11528390.

71. Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017; 170(6):1062–78. Epub 2017/09/09. https://doi.org/10.1016/j.cell.2017.08.028 PMID: 28886379; PubMed Central PMCID: PMC5743327.

72. Bowen ME, McLeod J, Long HK, Soreaya A, Van Nostrand JL, Wysocka J, et al. The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes. Dev Cell. 2019; 50(2):212–28 e6. Epub 2019/06/19. https://doi.org/10.1016/j.devcel.2019.05.015 PMID: 31178404; PubMed Central PMCID: PMC6650355.

73. Calo E, Gu B, Bowen ME, Arya F, Zalc A, Liang J, et al. Tissue-selective effects of nucleolar stress and DNA damage in developmental disorders. Nature. 2018; 554(7690):112–7. https://doi.org/10.1038/nature25449 PMID: 29364875; PubMed Central PMCID: PMC5927778.

74. Konstantinidou C, Taraviras S, Pachnis V. Geminin prevents DNA damage in vagal neural crest cells to ensure normal enteric neurogenesis. BMC biology. 2016; 14(1):94. Epub 2016/10/26. https://doi.org/10.1186/s12915-016-0314-x PMID: 27776507; PubMed Central PMCID: PMC5075986.

75. Fattahi F, Steinbeck JA, Kriks S, Tchieu J, Zimmer B, Kishinevsky S, et al. Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease. Nature. 2016. https://doi.org/10.1038/nature16951 PMID: 26863197.

76. Lai FP, Lau ST, Wong JK, Gui H, Wang RX, Zhou T, et al. Correction of Hirschsprung-associated mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function. Gastroenterology. 2017; 153(1):139–53 e8. Epub 2017/03/28. https://doi.org/10.1053/j.gastro.2017.03.014 PMID: 28342760.

77. Heuckeroth RO, Schafer KH. Gene-environment interactions and the enteric nervous system: Neural plasticity and Hirschsprung disease prevention. Dev Biol. 2016; 417(2):188–97. https://doi.org/10.1016/j.ydbio.2016.03.017 PMID: 26997034; PubMed Central PMCID: PMC5026873.

78. Sokal D, Dixon J, Achilleos A, Dixon M, Trainor PA. Prevention of Treacher Collins syndrome craniofacial anomalies in mouse models via maternal antioxidant supplementation. Nature communications. 2016; 7:10328. Epub 2016/01/23. https://doi.org/10.1038/ncomms10328 PMID: 26792133; PubMed Central PMCID: PMC4735750.

79. Nagy A, Gertsenstein M, Vintersten K, Behringer R. Manipulating the mouse embryo. A laboratory manual. 3rd Edition. Cold spring Harbor, New-York: Cold Spring Harbor Laboratory Press; 2003.

80. Method D, Reudelhuber TL, Silversides DW. Evaluation of tyrosinase minigene co-injection as a marker for genetic manipulations in transgenic mice. Nucleic Acids Res. 1995; 23(22):4551–6. PMID: 8524641.

81. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121):819–23. Epub 2013/01/03. https://doi.org/10.1126/science.1231143 PMID: 23287718.

82. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013; 153(4):910–8. https://doi.org/10.1016/j.cell.2013.04.025.

83. Belanger C, Berube-Simard FA, Leduc E, Bernas G, Campeau PM, Lalani SR, et al. Dysregulation of cotranscriptional alternative splicing underlies CHARGE syndrome. Proc Natl Acad Sci U S A. 2018; 115(4):E620–E9. https://doi.org/10.1073/pnas.1715378115 PMID: 29311329; PubMed Central PMCID: PMC5789929.
84. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001; 25(4):402–8. https://doi.org/10.1006/meth.2001.1262.

85. Liu L, Shi G, Thirumalai D, Hyeon C. Chain organization of human interphase chromosome determines the spatiotemporal dynamics of chromatin loci. PLoS Computational Biology. 2018; 14(12):e1006617. https://doi.org/10.1371/journal.pcbi.1006617

86. Du Z, Zheng H, Huang B, Ma R, Wu J, Zhang X, et al. Allelic reprogramming of 3D chromatin architecture during early mammalian development. Nature. 2017; 547(7662):232–5. Epub 2017/07/14. https://doi.org/10.1038/nature23263 PMID: 28703188.

87. Ke Y, Xu Y, Chen X, Feng S, Liu Z, Sun Y, et al. 3D Chromatin Structures of Mature Gametes and Structural Reprogramming during Mammalian Embryogenesis. Cell. 2017; 170(2):367–81.e20. Epub 2017/07/15. https://doi.org/10.1016/j.cell.2017.06.029 PMID: 28709003.

88. Enomoto H, Araki T, Jackman A, Heuckeroth RO, Snider WD, Johnson EM Jr., et al. GFR alpha1-deficient mice have deficits in the enteric nervous system and kidneys. Neuron. 1998; 21(2):317–24. PMID: 9728913.

89. Sanchez-Ferras O, Coutaud B, Djavanbakht Samani T, Tremblay I, Souchkova O, Pilon N. Caudal-related homeobox (Cdx) protein-dependent integration of canonical Wnt signaling on paired-box 3 (Pax3) neural crest enhancer. J Biol Chem. 2012; 287(20):16623–35. Epub 2012/03/30. M112.356394 [pii] https://doi.org/10.1074/jbc.M112.356394 PMID: 22457346; PubMed Central PMCID: PMC3351347.

90. Silversides DW, Raiwet DL, Souchkova O, Viger RS, Pilon N. Transgenic mouse analysis of Sry expression during the pre- and peri-implantation stage. Dev Dyn. 2012; 241(7):1192–204. Epub 2012/04/28. https://doi.org/10.1002/dvdy.23798 PMID: 22539273.